CELL INTELLIGENCE · 肿瘤细胞治疗研究

PARP 抑制剂联合安罗替尼作为卵巢癌装甲 CAR-T 细胞的桥接治疗可增强浸润与抗肿瘤疗效

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

靶向 MUC16 的膀胱内间皮素 CAR-T 细胞在临床前模型中有效控制膀胱癌

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

寻找 AML 中安全有效的 CAR-T 靶点

The search for safe and effective CAR-T targets in AML.

卵巢癌免疫治疗进展

Advances in immunotherapies in ovarian cancer.

年轻化造血干/祖细胞工程化 CAR 装甲自然杀伤 T 细胞用于恶性胸膜间皮瘤

Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma.

负载乙酰肝素酶的 CAR-T 细胞外囊泡重塑结直肠癌肿瘤微环境并增强 T 细胞抗肿瘤免疫

Heparanase-Loaded CAR T Extracellular Vesicles Remodel the Colorectal Tumour Microenvironment and Boost T Cell Antitumor Immunity.

膜结合 TRAIL 装甲增强 CAR-T 细胞在间皮素阳性实体瘤中的作用

Membrane-bound TRAIL-armoring augments CAR-T cells in mesothelin-positive solid malignancies.

我们的策略通过直接靶向异质性肿瘤抗原表达，相较已进入临床试验的 M28z CAR-T 细胞具有更优的抗肿瘤疗效。

Rab5 通过减少自相残杀并维持表面 CAR 水平改善 CAR-T 细胞疗效

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

将靶向间皮素的 CAR-T 细胞导向实体瘤

Directing mesothelin-targeted chimeric antigen receptor T cells to solid tumors.